For decades, medical students have been taught that allergies begin when the immune system overreacts to harmless substances, damaging the body's protective barriers in the process. But a team of researchers from Griffith University in Australia is challenging that long-held view, proposing instead that the root cause may lie in a power failure inside the cells that line the skin, gut, nose, lungs and oesophagus.
According to a study published in the journal Allergy, the researchers analysed what they describe as the largest multi-omic collection of allergy data they are aware of, covering 116 case-control cohorts, 3,776 patients, and 2,164 cohorts. The work was led by Professor Peter Smith, a clinical immunologist from Griffith's School of Medicine and Dentistry.
"For 60 years, we've taught that allergies start with the immune system and the barrier breaks as a consequence, but our work suggests it may be the other way around," Professor Smith said in a university news release.
The hypothesis centres on the mitochondria of epithelial cells — the cells that form the body's barrier surfaces. The researchers suggest that when these mitochondria fail to produce enough energy to cope with modern environmental stresses, the barrier cells raise an alarm too easily, triggering the immune response that manifests as an allergic reaction.
"Allergy diseases, which now affect up to one in three children, may start one step earlier as a power failure in the mitochondria of the epithelial cells," Professor Smith said. "The barrier cell can't meet the energy and stress demands of the modern environment so raises the alarm too easily, and the immune events we recognise as an allergy, follow."
This proposed mechanism could help explain why some children develop multiple allergic conditions simultaneously, such as eczema, food allergies, hay fever and asthma, according to the researchers.
The strongest evidence for the hypothesis was found in eosinophilic oesophagitis, an allergic disease of the gullet. In that condition, the cellular programme responsible for clearing damaged mitochondria was reduced across all 13 independent patient cohorts studied. In eczema, changes to the skin's barrier and antioxidant defences were detected even in skin that was not inflamed.
However, the signal was not present in every allergic condition. According to the Griffith report, it was absent in established asthma and nasal polyps, and only partially present in hay fever.
The paper also argues that many separate environmental triggers — including processed diets, pollution, microplastics, detergents, loss of dietary fibre and early antibiotic use — may all act on one shared target: the energy capacity of the barrier cell.
Co-author Associate Professor Nic West, a molecular immunologist from Griffith's School of Pharmacy and Medical Sciences, noted that allergies have long had too many potential causes and no single explanation for an epidemic that has multiplied within a single generation.
"The research also explains why allergies can relapse," Associate Professor West said. "Once inflammation is established it damages the barrier further. Today's drugs act downstream, so the disease often returns when treatment stops as they do not reach the root cause."
Professor Smith was careful to emphasise that the team views this as a hypothesis to be tested, not a settled mechanism. "We have spent our careers managing the smoke and for the first time we think we can see the fire, and it is not where everyone was looking," he said. "This is not a cure but is something we have never had before – a logical starting point."
The next step, according to the researchers, is to measure these cells directly in infants before allergies develop.
The study's co-authors came from institutions including Mount Sinai, KU Leuven, University College Cork, the University of Southampton, the University of Zurich, the University of Miami, the National University of Singapore and the University of Aberdeen.
For university students — many of whom may study medicine, biomedical science or public health — this research could represent a fundamental shift in how allergic diseases are understood and eventually treated. If the hypothesis holds up to further testing, it could open new avenues for therapies that target the mitochondrial dysfunction in barrier cells rather than just managing symptoms after the immune response has already begun.